L Number	Hits	Search Text	DB	Time stamp
1	4	"6616948"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 10:47
2	2	"6692770"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 10:49
3	5	"6706288"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 10:50
4	5	"6120787"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 10:54
5	542	514/60	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 10:54
6	417	514/60 and starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
7	106	(514/60 and starch) and amylopectin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
9	52	((514/60 and starch) and amylopectin) and gel	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
10	8	(((514/60 and starch) and amylopectin) and gel) and endotoxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:44
11	719	536/102	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
12	587	536/102 and starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
13	195	(536/102 and starch) and amylopectin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:43
14	118	((536/102 and starch) and amylopectin) and gel	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:44
15	4	(((536/102 and starch) and amylopectin) and gel) and endotoxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:49
16	214051	starch	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:50
17	5189	starch and amylopectin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:50

18	92	(starch and amylopectin) and (nitrogen NEAR content)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:50
19	28	((starch and amylopectin) and (nitrogen NEAR content)) and pharmaceutical	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:50
20	57	((starch and amylopectin) and (nitrogen NEAR content)) and gel	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:51
21	15	(((starch and amylopectin) and (nitrogen NEAR content)) and gel) and endotoxin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/07/26 11:51

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 22	STN Patent Forums to be held July 19-22, 2004
NEWS	8	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	9	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	10	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:31:30 ON 26 JUL 2004

=> file polymers

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (c) 2004 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 15:31:42 ON 26 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (c) 2004 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:31:42 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'DISSABS' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'PASCAL' ENTERED AT 15:31:42 ON 26 JUL 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 15:31:42 ON 26 JUL 2004
Copyright (C) 2004 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'TEXTILETECH' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 15:31:42 ON 26 JUL 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:31:42 ON 26 JUL 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 15:31:42 ON 26 JUL 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

```
=> s starch and (pharmaceutical or(pharmaceutical(w)grade)
UNMATCHED LEFT PARENTHESIS 'AND (PHARMACEUT'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=>  starch and (pharmaceutical or(pharmaceutical(w)grade))
STARCH IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s  starch and (pharmaceutical or(pharmaceutical(w)grade))
  20 FILES SEARCHED...
L1        97234 STARCH AND (PHARMACEUTICAL OR(PHARMACEUTICAL(W) GRADE))

=> s l1 and amylopectin
L2         2070 L1 AND AMYLOPECTIN

=> s l2 and (purity and (amino acid nitrogen)
UNMATCHED LEFT PARENTHESIS 'AND (PURITY'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l2 and purity and (amino acid nitrogen)
   7 FILES SEARCHED...
  16 FILES SEARCHED...
  17 FILES SEARCHED...
L3           21 L2 AND PURITY AND (AMINO ACID NITROGEN)

=> s l3 and gel
L4           21 L3 AND GEL

=> s l4 and endotoxin
L5           21 L4 AND ENDOTOXIN

=> dis l5 1-21 bib abs

L5   ANSWER 1 OF 21  USPATFULL on STN
AN     2004:151060  USPATFULL
TI     Microparticles
IN     Gustavsson, Nils Ove, Loddekopinge, SWEDEN
       Jonsson, Monica, Bara, SWEDEN
       Laakso, Timo, Campton, UNITED KINGDOM
       Reslow, Mats, Lund, SWEDEN
PI     US 2004115281      A1   20040617
AI     US 2003-705204     A1   20031110 (10)
RLI    Continuation of Ser. No. US 2001-970793, filed on 5 Oct 2001, GRANTED,
       Pat. No. US 6706288
DT     Utility
FS     APPLICATION
LREP   Richard H. Newman, Esq., Edwards & Angell, LLP, P.O. Box 9169, Boston,
       MA, 02209
CLMN   Number of Claims: 46
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1758
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     A process for producing parenterally administrable microparticles, in
       which an at least 20% by weight aqueous solution of purified
       amylopectin-based starch of reduced molecular weight
       is prepared, the solution is combined with biologically active
       substance, an emulsion of starch droplets is formed in an
       outer phase of polymer solution, the starch droplets are made
       to gel, and the gelled starch particles are dried. A
       release-controlling shell is optionally also applied to the particles.
```

Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 21 USPATFULL on STN
AN 2004:25172 USPATFULL
TI Pharmaceutically acceptable **starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berden, Per, Malmo, SWEDEN
Laakso, Timo, Bedfordshire, UNITED KINGDOM
PA JAGOTEC AG., Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 2004019014 A1 20040129
AI US 2003-627920 A1 20030728 (10)
RLI Division of Ser. No. US 2001-970648, filed on 5 Oct 2001, PENDING
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, dissolving the **starch** in aqueous medium, molecular weight reduction by shearing, and optionally removal of residual water-soluble proteins, preferably by anion exchange chromatography.

Purified **starch** and microparticles based on such **starch.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 21 USPATFULL on STN
AN 2003:299946 USPATFULL
TI Microparticles
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 2003211167 A1 20031113
US 6692770 B2 20040217
AI US 2003-461445 A1 20030616 (10)
RLI Division of Ser. No. US 2001-970793, filed on 5 Oct 2001, PENDING
PRAI SE 2000-3615 20001006
US 2001-260455P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1756
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for producing parenterally administrable microparticles, in which an at least 20% by weight aqueous solution of purified **amylopectin**-based **starch** of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of **starch** droplets is formed in an outer phase of polymer solution, the **starch** droplets are made to **gel**, and the gelled **starch** particles are dried. A release-controlling shell is optionally also applied to the particles.

Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 21 USPATFULL on STN
AN 2003:293948 USPATFULL
TI **Starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berdeh, Per, Malmo, SWEDEN
Laakso, Timo, Bedfordshire, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 2003206961 A1 20031106
AI US 2003-461393 A1 20030616 (10)
RLI Division of Ser. No. US 2001-970795, filed on 5 Oct 2001, GRANTED, Pat. No. US 6616948
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS APPLICATION
LREP BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1129
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, subjecting the **starch** to a molecular weight reduction by acid hydrolysis, and optionally removing residual water-soluble proteins.

Purified **starch** and microparticles based on such **starch**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 21 USPATFULL on STN
AN 2003:257321 USPATFULL
TI Microparticles
IN Reslow, Mats, Lund, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Larsson, Karin, Torna Hallestad, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
PI US 2003180371 A1 20030925
AI US 2002-162674 A1 20020606 (10)
PRAI SE 2002-873 20020321
SE 2002-1599 20020530
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box

1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 78
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing microparticles, in which an aqueous solution of purified **amylopectin**-based **starch** of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of **starch** droplets is formed in an outer phase of polymer solution, the **starch** droplets are made to **gel**, the gelled **starch** particles are dried, and a release-controlling shell is optionally applied to the particles, wherein at least one buffer substance having the ability of keeping the pH of the produced microparticles above 3 if exposing the microparticles to an aqueous evironment is added at any stage during the process.

Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking and which have the aktivity of keeping the pH above 3 if exposed to a aqueous environment,

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 21 USPATFULL on STN
AN 2003:29848 USPATFULL
TI Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
IN Hsei, Vanessa, San Jose, CA, UNITED STATES
Koumenis, Iphigenia, Palo Alto, CA, UNITED STATES
Leong, Steven, Berkeley, CA, UNITED STATES
Presta, Leonard, San Francisco, CA, UNITED STATES
Shahrokh, Zahra, San Francisco, CA, UNITED STATES
Zapata, Gerardo, St. Foster City, CA, UNITED STATES
PA Genentech, Inc. (U.S. corporation)
PI US 2003021790 A1 20030130
AI US 2000-726258 A1 20001129 (9)
RLI Continuation of Ser. No. US 1999-234182, filed on 20 Jan 1999, PENDING
PRAI US 1998-74330P 19980122 (60)
US 1998-94013P 19980724 (60)
US 1998-94003P 19980724 (60)
US 1998-75467P 19980220 (60)
DT Utility
FS APPLICATION
LREP Knobbe Martens Olson & Bear LLP, Ginger R Dreger, Sixteenth Floor, 620 Newport Center Drive, Newport Beach, CA, 92660
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 142 Drawing Page(s)
LN.CNT 10643
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD, The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 21 USPATFULL on STN
AN 2002:275741 USPATFULL
TI Methods of treating inflammatory diseases with anti-IL-8 antibody

fragment-polymer conjugates
IN Hsei, Vanessa, San Jose, CA, United States
Koumenis, Iphigenia, Palo Alto, CA, United States
Leong, Steven, Berkeley, CA, United States
Presta, Leonard, San Francisco, CA, United States
Shahrokh, Zahra, San Francisco, CA, United States
Zapata, Gerardo, Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6468532 B1 20021022
AI US 1999-234340 19990120 (9)
PRAI US 1998-94013P 19980724 (60)
US 1998-94003P 19980724 (60)
US 1998-75467P 19980220 (60)
US 1998-74330P 19980122 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mertz, Prema; Assistant Examiner: Hamud, Fozia
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 161 Drawing Figure(s); 142 Drawing Page(s)
LN.CNT 10647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 21 USPATFULL on STN
AN 2002:254046 USPATFULL
TI Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
IN Hsei, Vanessa, San Jose, CA, United States
Koumenis, Iphigenia, Palo Alto, CA, United States
Leong, Steven, Berkeley, CA, United States
Presta, Leonard, San Francisco, CA, United States
Shahrokh, Zahra, San Francisco, CA, United States
Zapata, Gerardo, St. Foster, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6458355 B1 20021001
AI US 1998-121952 19980724 (9)
PRAI US 1998-74330P 19980122 (60)
US 1998-75467P 19980220 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Mertz, Prema; Assistant Examiner: Hamud, Fozia
LREP Knobbe, Martens, Olson & Bear, LLP
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 161 Drawing Figure(s); 142 Drawing Page(s)
LN.CNT 10658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate

is at least about 500 kD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 21 USPATFULL on STN
AN 2002:191248 USPATFULL
TI Microparticle preparation
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
Bjorn, Soren, Lyngby, DENMARK
Drustrup, Jorn, Farum, DENMARK
PI US 2002102311 A1 20020801
AI US 2002-970792 A1 20020110 (9)
PRAI SE 2000-3614 20001006
US 2001-260495P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A parenterally administrable, biodegradable microparticle preparation containing a biologically active substance which, during the first 24 hours after injection, exhibits a release of the active substance that is less than 25% of the total release, determined from a concentration-time curve in the form of the ratio between the area under the curve during the said first 24 hours and the total area under the curve in question

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 21 USPATFULL on STN
AN 2002:185295 USPATFULL
TI Vaccine composition
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
Larsson, Karin, Torna Hallestad, SWEDEN
PI US 2002098203 A1 20020725
AI US 2002-970794 A1 20020110 (9)
PRAI SE 2000-3615 20001006
US 2001-260455P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A vaccine composition which comprises an immnunologically active substance embedded in microparticles essentially consisting of **starch** having an **amylopectin** content exceeding 85% by weight, of which at least 80% by weight has an average molecular weight within the range of 10-10000 kDa, and without any covalent chemical cross-linking between the **starch** molecules.

A process for preparing such vaccine composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 21 USPATFULL on STN
AN 2002:156739 USPATFULL
TI Parenterally administrable microparticles
IN Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PI US 2002081336 A1 20020627
AI US 2001-970649 A1 20011005 (9)
PRAI SE 2000-4218 20001116
US 2001-260496P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 57
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1679
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing microparticles containing biologically active substance, in which process an aqueous solution of the said substance is prepared, this solution is mixed with an aqueous solution of PEG such that the substance is concentrated and/or solidified, the substance is optionally washed, the substance is mixed with an aqueous **starch** solution, the composition obtained is mixed, after the admixture of the **starch** solution, with a polymer solution, thereby forming an emulsion of **starch** droplets in the polymer solution, the **starch** droplets are solidified into microparticles, the microparticles are dried and a release-controlling shell is optionally applied to these.

Novel microparticles which are obtainable by means of this process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 21 USPATFULL on STN
AN 2002:126893 USPATFULL
TI **Starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berden, Per, Malmo, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PI US 2002065411 A1 20020530
US 6616948 B2 20030909
AI US 2001-970795 A1 20011005 (9)
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, subjecting the **starch** to a molecular weight reduction by acid hydrolysis, and optionally removing residual

water-soluble proteins.

Purified **starch** and microparticles based on such **starch.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 21 USPATFULL on STN
AN 2002:85699 USPATFULL
TI Pharmaceutically acceptable **starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berden, Per, Malmo, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PI US 2002045745 A1 20020418
US 6689389 B2 20040210
AI US 2001-970648 A1 20011005 (9)
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, dissolving the **starch** in aqueous medium, molecular weight reduction by shearing, and optionally removal of residual water-soluble proteins, preferably by anion exchange chromatography.

Purified **starch** and microparticles based on such **starch.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 21 USPATFULL on STN
AN 2002:84936 USPATFULL
TI Microparticles
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PI US 2002044976 A1 20020418
US 6706288 B2 20040316
AI US 2001-970793 A1 20011005 (9)
PRAI SE 2000-3615 20001006
US 2001-260455P 20010108 (60)
DT Utility
FS APPLICATION
LREP Benton S. Duffett, Jr., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing parenterally administrable microparticles, in which an at least 20% by weight aqueous solution of purified

amylopectin-based **starch** of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of **starch** droplets is formed in an outer phase of polymer solution, the **starch** droplets are made to **gel**, and the gelled **starch** particles are dried. A release-controlling shell is optionally also applied to the particles.

Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 21 USPATFULL on STN
AN 2000:138511 USPATFULL
TI Humanized anti-IL-8 monoclonal antibodies
IN Gonzalez, Tania N., Oakland, CA, United States
Leong, Steven R., Berkeley, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6133426 20001017
AI US 1998-26985 19980220 (9)
PRAI US 1997-38664P 19970221 (60)
US 1998-74330P 19980122 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Mertz, Prema
LREP Love, Richard B.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 136 Drawing Figure(s); 136 Drawing Page(s)
LN.CNT 9465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 21 USPATFULL on STN
AN 2000:18244 USPATFULL
TI Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
IN Gonzalez, Tania N., Oakland, CA, United States
Leong, Steven R., Berkeley, CA, United States
Presta, Leonard G., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6025158 20000215
AI US 1998-27449 19980220 (9)
PRAI US 1997-38664P 19970221 (60)
US 1998-74330P 19980122 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Mertz, Prema
LREP Love, Richard B.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 130 Drawing Figure(s); 136 Drawing Page(s)
LN.CNT 9492

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 21 USPAT2 on STN
AN 2003:299946 USPAT2
TI **Starch** microparticles
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 6692770 B2 20040217
AI US 2003-461445 20030616 (10)
RLI Division of Ser. No. US 2001-970793, filed on 5 Oct 2001
PRAI SE 2000-3615 20001006
US 2001-260455P 20010108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Edwards & Angell, LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1709
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing parenterally administrable microparticles, in which an at least 20% by weight aqueous solution of purified **amylopectin**-based **starch** of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of **starch** droplets is formed in an outer phase of polymer solution, the **starch** droplets are med to **gel**, and the gelled **starch** particles are dried. A release-controlling shell is optionally also applied to the particles. Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 21 USPAT2 on STN
AN 2002:126893 USPAT2
TI **Starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berden, Per, Malmo, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 6616948 B2 20030909
AI US 2001-970795 20011005 (9)
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, subjecting the **starch** to a molecular weight reduction by acid hydrolysis, and optionally removing residual water-soluble proteins.

Purified **starch** and microparticles based on such **starch.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 21 USPAT2 on STN
AN 2002:85699 USPAT2
TI Pharmaceutically acceptable **starch**
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Berden, Per, Malmo, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 6689389 B2 20040210
AI US 2001-970648 20011005 (9)
PRAI SE 2000-3616 20001006
US 2001-260491P 20010108 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Wang, Shengjun
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1168
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Production of purified, parenterally administrable **starch** by washing **starch** containing more than 85% **amylopectin** in order to remove surface-localized proteins, lipids and **endotoxins**, dissolving the **starch** in aqueous medium, molecular weight reduction by shearing, and optionally removal of residual water-soluble proteins, preferably by anion exchange chromatography.

Purified **starch** and microparticles based on such **starch.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 21 USPAT2 on STN
AN 2002:84936 USPAT2
TI Microparticles
IN Gustavsson, Nils Ove, Loddekopinge, SWEDEN
Jonsson, Monica, Bara, SWEDEN
Laakso, Timo, Campton, UNITED KINGDOM
Reslow, Mats, Lund, SWEDEN
PA Jagotec AG, Muttenz, SWITZERLAND (non-U.S. corporation)
PI US 6706288 B2 20040316
AI US 2001-970793 20011005 (9)
PRAI SE 2000-3615 20001006
US 2001-260455P 20010108 (60)
DT Utility

FS GRANTED
EXNAM Primary Examiner: Azpuru, Carlos A.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1735
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for producing parenterally administrable microparticles, in which an at least 20% by weight aqueous solution of purified **amylopectin**-based **starch** of reduced molecular weight is prepared, the solution is combined with biologically active substance, an emulsion of **starch** droplets is formed in an outer phase of polymer solution, the **starch** droplets are made to **gel**, and the gelled **starch** particles are dried. A release-controlling shell is optionally also applied to the particles.

Microparticles which essentially consist of said **starch**, have an amino acid content of less than 50 μg and have no covalent chemical cross-linking.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 21 WPINDEX COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2004-080353 [08] WPINDEX
DNC C2004-033011
TI Microparticles useful for controlled release of biologically active substances comprise buffer substance(s) and **starch** containing specified **amylopectin** and **amino acid** **nitrogen** contents, and have no covalent chemical crosslinking.
DC A11 A96 B04 B07 D16
IN JONSSON, M; LAAKSO, T; LARSSON, K; RESLOW, M; JOENSSON, M
PA (JONS-I) JONSSON M; (LAAK-I) LAAKSO T; (LARS-I) LARSSON K; (RESL-I) RESLOW M; (JAGO-N) JAGOTEC AG
CYC 103
PI US 2003180371 A1 20030925 (200408)* 20
WO 2003080033 A1 20031002 (200408) EN
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
AU 2003212776 A1 20031008 (200432)
ADT US 2003180371 A1 US 2002-162674 20020606; WO 2003080033 A1 WO 2003-SE463 20030320; AU 2003212776 A1 AU 2003-212776 20030320
FDT AU 2003212776 A1 Based on WO 2003080033
PRAI SE 2002-1599 20020530; SE 2002-873 20020321
AN 2004-080353 [08] WPINDEX
AB US2003180371 A UPAB: 20040202
NOVELTY - Microparticles containing a biologically active substance comprise **starch** having an **amylopectin** content exceeding 85 weight% and an **amino acid nitrogen** content of less than 50 micro g per gram dry weight of **starch**, are new. The microparticles have no covalent chemical crosslinking between the **starch** molecules, and contain buffer substance(s) to keep the pH of the produced microparticles above 3 if exposed to an aqueous environment.

DETAILED DESCRIPTION - Microparticles containing a biologically active substance comprise **starch** having an **amylopectin** content exceeding 85 weight%, at least 80 weight% of which has an average molecular weight of 10-10000 kDa, and having an **amino** **acid nitrogen** content of less than 50 mu g per gram dry weight of **starch.** The microparticles have no covalent chemical

crosslinking between the **starch** molecules, and contain at least one buffer substance that keeps the pH of the produced microparticles above 3 if exposing the microparticles to an aqueous environment, e.g. at injection into a mammal including man.

An INDEPENDENT CLAIM is also included for a process for producing microparticles containing biologically active substance, which involves:

(a) preparing an aqueous **starch** solution comprising **starch** which has an **amylopectin** content exceeding 65 weight%, in which the molecular weight of the **amylopectin** has been reduced such that at least 80 weight% of the material is 10-10000 kDa, and which has an **amino acid nitrogen** content of less than 50 micro g per g dry weight of **starch**;

(b) combining the biologically active substance with the **starch** solution under such conditions that a composition in the form of a solution, emulsion, or suspension of the substance in the **starch** solution is formed;

(c) mixing the composition with an aqueous solution of a polymer having the ability of forming a two-phase aqueous system, thus forming an emulsion of **starch** droplets which contain the biologically active substance as an inner phase in an outer phase of the polymer solution; causing or allowing the **starch** droplets to **gel** into **starch** particles through the natural capacity of the **starch** to solidify;

(d) drying the **starch** particles, preferably after prior removal of the outer phase through washing; and

(e) optionally applying a release-controlling shell of a biocompatible and biodegradable polymer, preferably by air suspension technology to the dried **starch** particles. At least one buffer substance having the ability to keep the pH of the produced microparticles to an aqueous environment, e.g. by injection into a mammal including man, is added at any stage during the process.

USE - The microparticles are useful for controlled release for parenteral administration of biologically active substances, especially drugs, to a mammal, especially human.

ADVANTAGE - The inventive microparticles create a good microclimate for the biologically active substance incorporated in the microparticles such that the bioactivity of the substance is maintained during the manufacturing process as well as after administration.

Dwg.0/1

```
=> dis hist

     (FILE 'HOME' ENTERED AT 15:31:30 ON 26 JUL 2004)

     FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, DISSABS, EMA, IFIPAT,
     JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH,
     USPATFULL, USPAT2, WPIFV, WPINDEX, WTEXTILES' ENTERED AT 15:31:42 ON 26
     JUL 2004
L1          97234 S  STARCH AND (PHARMACEUTICAL OR(PHARMACEUTICAL(W)GRADE))
L2           2070 S L1 AND AMYLOPECTIN
L3             21 S L2 AND PURITY AND (AMINO ACID NITROGEN)
L4             21 S L3 AND GEL
L5             21 S L4 AND ENDOTOXIN

=>

---Logging off of STN---


=>
Executing the logoff script...
```

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	106.98	107.19

STN INTERNATIONAL LOGOFF AT 15:38:02 ON 26 JUL 2004